CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Marc de Garidel

Chief Executive Officer, ABIVAX Société Anonyme

Search every verified Marc de Garidel interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Marc de Garidel, CEO of Abivax, has discussed the company's progress with its lead drug candidate obefazimod for ulcerative colitis. Following positive Phase 3 results, he noted that the company raised $750 million in a single day after the announcement, with $3.1 billion in demand that briefly halted trading on both Euronext and Nasdaq. He described the drug's potential as a first oral treatment before biologic therapies, citing data showing that two-thirds of patients who responded within eight weeks were in remission after two years. De Garidel stated that the global market for ulcerative colitis is estimated at around $30 billion at launch, with 70% in the United States. De Garidel has also commented on the broader biotech environment, noting that 27% of public biotech companies had negative enterprise value in early 2025. He emphasized the importance of raising cash during positive news cycles, stating "you don't die from dilution, you die if you don't have cash." He attributed Abivax's success to its team, saying "I'm only the chief of the orchestra; the people who play the music are the people around me." De Garidel has advised aspiring leaders to "do what you like" and not to worry excessively about others' opinions, adding that he has made mistakes in his career but views risk-taking as essential for building meaningful companies.

Recent appearances

  • PODCAST PHARMA MINDS - PAUL BRAVETTI (CEO Brenus Pharma) et MARC DE GARIDEL (CEO Abivax)

    January 29, 2026 · 📺 Brenus Pharma

    Quand le cash devient critique, comment prendre les bonnes décisions sans compromettre l’avenir de votre biotech ? Jusqu’où dérisquer, lever des fonds ou investir pour créer une véritable valeur thérapeutique ? 🎂 Pour ce 50ᵉ épisode de Pharma Minds, j’ai choisi un format inédit, avec deux invités. L’objectif : mettre en lumière les décisions stratégiques en biotech que les dirigeants ne peuvent plus éviter aujourd’hui. Autour de la table : 👉 Paul Bravetti, CEO de Brenus Pharma, biotech innovante en oncologie qui entre en clinique, 👉 Et Marc de Garidel, CEO d’Abivax, biotech cotée engagée d…

    Watch on YouTube ↗

  • Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46

    November 21, 2025 · 📺 FlotBio x Philip Hemme

    When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround. Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team. ⭐️ ABOUT THE SPEAKER Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinC…

    Watch on YouTube ↗

  • Le Journal des biotechs : Pascal Prigent (Genfit) Marc de Garidel (Abivax)

    October 01, 2025 · 📺 Boursorama

    Numéro un peu particulier du Journal des biotechs, sans point d'actualité mais avec deux entretiens. Le premier est consacré à Pascal Prigent qui revient notamment sur l'arrêt du programme VS-01 dans l'ACLF et réaffirme la stratégie de Genfit dans cette indication. Marc de Garidel revient lui sur le succès des résultats de phase III de l'Obefazimod dans la RCH. Il livre ses priorités stratégiques pour Abivax dans les mois à venir. #boursorama #Biotech #Santé ___________________________________________________________________________________________________ → Retrouvez l'ensemble des épisodes…

    Watch on YouTube ↗

  • The BioHub – The Avetix Podcast – S2 Ep50 – Marc de Garidel & Sylvie Grégoire

    May 27, 2025 · 📺 Avetix Group

    Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. In this special follow-up episode, I’m rejoined by Marc de Garidel, CEO of Abivax, after our hugely popular conversation last year—recorded just after their record-breaking NASDAQ IPO. That episode gave us a look into Marc’s incredible career, the company’s bold vision, and how they were gearing up to become a major player in inflammatory diseases. This time, he’s joined by Sylvie Grégoire, Chair of the Abivax Board—a hugely respected industry leader with decades of global biotech and…

    Watch on YouTube ↗

  • Do What You Enjoy – Marc de Garidel

    February 11, 2024 · 📺 SpreadLoveio

    We welcomed in this first episode, Marc De Garidel Chief Executive Officer at Abivax. Marc shared his personal story and ...

    Watch on YouTube ↗

  • The BioHub - The Avetix Podcast - Episode 4 - Marc De Garidel

    January 30, 2024 · 📺 Avetix Group

    Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. 40 years of experience across biotech and pharma! 6 years as CEO of Ipsen, where he currently serves as Chairman. He led the successful sale of Cincor Pharma for 1.8 Billion dollars to Astrazeneca and the sale of Corvidia to Novo Nordisk for 2.1 billion dollars. Now he serves as the CEO of Abivax, who just completed the largest ever NASDAQ IPO for a French biotech! Enjoy and stay tuned

    Watch on YouTube ↗

  • Marc de Garidel, Abivax 🇫🇷 | "Smooth" Billion Biotech Exits | E09

    December 04, 2023 · 📺 FlotBio x Philip Hemme

    Today, I’m in Paris to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca in 2023. I’ve never met Marc but I…

    Watch on YouTube ↗

  • CEO Marc De Garidel On Building Something Truly Impactful: Embrace Risks!

    November 19, 2023 · 📺 Pharma minds

    00:00 Intro 01:35 Hello Marc! 02:53 Where does he come from? 04:42 Starting with a diploma as a civil engineer 06:30 Beginning a career in finance with Eli Lilly 07:20 Entering the biotech world with Amgen 08:52 The 1st important decision reveals he likes taking risk 10:01 Anecdote related to his detail attention in the beginning 12:17 From knowing the details to ask to the good questions 14:15 Ask simple questions 15:08 His 4 attributes of a good leader 17:35 How he knew where he wanted to go 19:14 His profound driver 22:30 When he knew he wanted to be a CEO 24:55 Important vs urgent decision…

    Watch on YouTube ↗

  • Le Journal des biotechs : Marc de Garidel (Abivax)

    November 17, 2023 · 📺 Boursorama

    Dans ce numéro hors série du Journal des biotechs, Marc de Garidel, PDG d'Abivax vient faire le point sur la situation de la biotech après l'introduction réussie au Nasdaq. Il détaille le déroulement de l'essai de Phase III dans la RCH et explique notamment le positionnement d'Abivax par rapport à ses concurrents directs. #Boursorama #Biotech #Santé ___________________________________________________________________________________________________ → Retrouvez l'ensemble des épisodes du Journal des Biotechs, le point sur l'actualité des sociétés de santés innovantes, ici : https://www.boursoram…

    Watch on YouTube ↗

  • Interview of Marc de Garidel - Achievements in 2015 and future prospects

    June 21, 2016 · 📺 Ipsen

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →